PetIQ, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals: Major
  • ISIN: US71639T1060
USD
30.98
-0.01 (-0.03%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About PetIQ, Inc. stock-summary
stock-summary
PetIQ, Inc.
Pharmaceuticals: Major
PetIQ, Inc. is engaged in manufacturing and distributing pet medication and health and wellness products to the retail channel in the United States. The Company provides retail stores with third-party brands, including Frontline Plus, Heartgard Plus, PetAction Plus, Advecta II, Pet Lock Plus, Pet Lock Max, TruProfen and Heartshield. It distributes the products through veterinarian, retail and e-commerce channels. The Company offers its products in a range of categories, including Rx Medications, OTC Medications and Supplies, and Health and Wellness Products. Rx Medications offering includes heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics and other specialty medications. The Company manufactures Heart Shield Plus, version of Heartgard Plus, which prevents heartworm infection in dogs. The Company also manufactures TruProfen, the version of Rimadyl, which treats arthritis in dogs. OTC Medications and Supplies include flea and tick control products.
Company Coordinates stock-summary
Company Details
923 S Bridgeway Pl , EAGLE ID : 83616-6885
stock-summary
Tel: 1 208 93989001 646 2771263
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 61 Schemes (37.03%)

Foreign Institutions

Held by 89 Foreign Institutions (13.33%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. McCord Christensen
Chairman of the Board, Chief Executive Officer
Mr. Mark First
Lead Independent Director
Mr. Will Santana
Director
Mr. Larry Bird
Independent Director
Mr. James Clarke
Independent Director
Mr. Scott Huff
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
329 Million
(Quarterly Results - Jun 2024)
Net Profit:
15 Million
stock-summary
Industry

Pharmaceuticals: Major

stock-summary
Market cap

USD 938 Million (Micro Cap)

stock-summary
P/E

27.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

97.25%

stock-summary
Debt Equity

1.41

stock-summary
Return on Equity

13.41%

stock-summary
Price to Book

3.64